Thanks to the pioneering work of Belhocine et al., using 99mTc-BTAP-Annexin A5 to monitor chemosensitivity in a variety of cancer types (e.g., lung cancer, lymphoma and breast cancer), clinical studies investigating the various tracers described above followed [46,47,48,49,50]. This evidence concerns the gene ANXA5 and lymphoma.